dc.contributor.author |
Alexandrova, N.V. |
|
dc.contributor.author |
Alekhina, I.Y. |
|
dc.contributor.author |
Alexandrov, A.V. |
|
dc.contributor.author |
Zborovskaja, I.A. |
|
dc.date.accessioned |
2021-03-02T08:23:06Z |
|
dc.date.available |
2021-03-02T08:23:06Z |
|
dc.date.issued |
2011 |
|
dc.identifier.citation |
ALEXANDROVA, N.V., ALEKHINA, I.Y., ALEXANDROV, A.V., ZBOROVSKAJA, I.A. Autoantibodies to adenozine deaminase as marker of immunological disorders in systemic lupus erythematosus. In: Sănătate Publică, Economie şi Management în Medicină. 2011, nr. 2(2), pp. 59-60. ISSN 1729-8687. |
en_US |
dc.identifier.issn |
1729-8687 |
|
dc.identifier.uri |
http://revistaspemm.md/wp-content/uploads/2019/05/cm2_2_2011.pdf |
|
dc.identifier.uri |
http://repository.usmf.md/handle/20.500.12710/15988 |
|
dc.description |
Conferinţa naţională în medicina internă din Republica Moldova cu participare internaţională, 19-20 mai 2011, Chişinău, Republica Moldova |
en_US |
dc.description.abstract |
Objectives. The autoantibodies to various enzymes
are often found out in sera of systemic lupus
erythematosus (SLE) patients, but clinical value of
such antibodies often is not understood.
Purpose. The purpose of work was to study
the of antibodies generation to the basic enzyme of
purine metabolism – Adenozine Deaminase (ADA)
in SLE and to reveal the relationship of studied
antibodies with clinical and laboratory features of
pathological process.
Methods. 30 healthy persons have been included
in our study and 71 SLE patients (66 women
and 5 men) with various clinical signs (44 persons
had 1st degree of disease activity, 27 persons – 2nd
degree of pathological process activity). 18 women
had habitual noncarrying of pregnancy (HNP) in
anamnesis. Antibodies of IgG class to ADA (anti-
ADA) determined by technique of indirect ELISA
developed by us with the use of immobilized form
of ADA as an antigenic matrix. β2-glicoprotein-I-dependent
antiphospholipids (aPhL) of IgG and IgМ
classes were determined using commercial „Anti-
Phospholipid Screen IgG/IgM” test set (Orgentec
Diagnostica).
Results. At admission an anti-ADA was revealed
in 36,6%, aPhL of IgG class – in 45,1%, and
aPhL of IgМ class – in 23 (32,4%) SLE patients. It
has been noted that IgG- aPhL were found out
in anti-ADA-positive patients more often and in
higher antibody titer, than in anti-ADA-negative
SLE patients (χ2 =6,4; р <0,02). Development of cytopenic
syndrome was noted reliable more often
in SLE patients with associated presence of IgGaPhL
and an anti-ADA in comparison with patients
who has not the combinations of these antibodies
in blood (χ2 = 3,9; р <0,05). The increased levels of
anti-ADA were revealed in 11 of 18 women with
HNP, and the combination of anti-ADA and aPhL
(9/18) was found out more often than isolated
anti-ADA (2/18, χ2 =6,5; р <0,02) or isolated aPhL
(3/18, χ2 =4,5; р <0,05).
Conclusion. Taking into account the imbalance
of immunoregulatory functions in SLE, the further
studying of autoantibodies to ADA generation seems to be very promising. Presence of HNP in anamnesis
is the evidence of necessity of careful biochemical
monitoring of aPhL and anti-ADA in women for the
prevention of abortus fetus and administration of
adequate therapy. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Asociația Obștească ”Economie, Management și Psihologie în Medicină” din Republica Moldova |
en_US |
dc.relation.ispartof |
Sănătate Publică, Economie și Management în Medicină: Conferinţa naţională în medicina internă din Republica Moldova cu participare internaţională, 19-20 mai 2011, Chişinău, Republica Moldova |
en_US |
dc.title |
Autoantibodies to adenozine deaminase as marker of immunological disorders in systemic lupus erythematosus |
en_US |
dc.type |
Other |
en_US |